Royalty Report: Drugs, Pharmaceuticals, Pain – Collection: 6681


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Pain
  • Personal Care Products
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6681

License Grant
The British Virgin Island Licensor hereby grants to the Hong Kong Licensee, an equally-owned joint-venture,  exclusive and non-transferable Manufacturing Rights and Distribution Rights for the Products and to use the Intellectual Property Rights in each Country in the Territory for the duration of the Term to the extent required to practice the exclusive rights granted herein to the Products, provided such Products conform to the Standards of Quality defined in the Agreement.
License Property
LIST OF PRODUCTS  1% Indaflex (1% Indomethacin); 1% Diclofenac; Flexogan (6% Menthol, 6% Camphor, 16% Methyl Salicylate).  Flexogan is an over-the-counter, deep penetrating topical cream that provides temporary relief from pain associated with joints, muscles and minor arthritis.

Chinese Patent Application No. 03165005.8 Title Vehicle for Topical deliver of Anti-Inflammatory Compounds.

Field of Use
Field means the use of the Products in pain management and inflammation treatment.

IPSCIO Record ID: 3032

License Grant
The Licensee has entered into a License and manufacturing Agreement with the Licensor who is the patent owner of the liposomal delivery system used in ALCiS Daily Relief.

The Agreement grants the Licensee an exclusive, world-wide License for the commercialization of the liposomal delivery system for topical analgesic pain relief applications and body soak preparations and a non-exclusive, world-wide License for the commercialization of the liposomal delivery system for similar preparations such as body lotions and soap.

On April 13, 2006 the licensing and manufacturing Agreement was amended to provide for a grant to the Manufacturer of warrants to purchase 560,000 shares of the Company’s common stock.

License Property
The Licensor is currently the Licensee's sole provider of ALCiS Daily Relief.  ALCiS Daily Relief is a fast-acting, clean-scented pain relief cream. The advanced, patented technology found in the product delivers the active ingredient quickly, with results in as little as five minutes.
Field of Use
ALCiS Daily Relief can be used for the temporary relief of minor aches and pains of muscles and joints associated with strains, sprains, simple backache, bruises, sports injuries and arthritis.  Field of Use relates to the medical industry.

IPSCIO Record ID: 26321

License Grant
The Licensor signed a License Agreement with the Licensee for Indaflex.

Under the terms of the Agreement executed the Licensor could receive up to $116 million in milestone payments on achievement of all regulatory and revenue targets. In addition the Licensee assumes all clinical and commercialization costs, in return for full commercialization and sub-licensing rights in the U.S and other regions.

License Property
Indaflex(TM) is topical NSAID (Non-Steroidal Anti-inflammatory Drug) formulation intended to start clinical development soon for use in the treatment symptoms of arthritis.  The product is currently in Phase II clinical development for the reduction of signs and symptoms associated with osteoarthritis of the knee.

Indaflexâ„¢ Cream is a semi-solid formulation for topical administration, containing the active ingredient Indomethacin, at a concentration of 2.5%. Indaflexâ„¢ Cream is an innovative oil-in-water emulsion formulation. There are three main features of this product which contribute to its improved efficacy as a topical analgesic drug loading/concentration, a nanoparticulate oil-in-water emulsion formulation and an improved partitioning of lipophilic drug from nanoparticles into the lipid matrix of the absorbing tissue.

Indaflexâ„¢ Cream is composed of a highly dispersed colloidal suspension of nano-sized oil droplets, loaded with active drug and suspended in an aqueous phase.

Field of Use
Indaflex is a non-steroidal anti-inflammatory drug, typically prescribed in order to manage symptoms such as pain, fever, swelling and stiffness. This medication acts as an inhibitor of prostaglandin production – prostaglandins are the agents that are known to induce these symptoms.

IPSCIO Record ID: 26558

License Grant
The Mexican Licensee has the Exclusive and non-transferable manufacturing rights and distribution rights in Mexico for Indaflex.
License Property
A Canadian pharma Licensed Indaflex, a lead pharmaceutical product under development for commercialization in Mexico. Licensor owns and/or has rights to the Intellectual Property Rights  relating to a pharmaceutical agent for pain control and inflammation treatment;

Indaflex is a topical NSAID formulation intended to be used in the treatment of arthritis. Indaflex is our only prescription drug at the clinical trial stage.

Field of Use
Field of Use relates to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.